The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000859381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/06/2026
Date registered
Help: Date registered
14/07/2026
Date last updated
Help: Date last updated
14/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
The Effect of Traditional, Menstrual Cycle Phase-based, and Symptom-based Autoregulatory Resistance Training on Neuromuscular Function, Sleep and Nocturnal Physiology, and Perceived Well-being and Training Load in Healthy Female Adults
Scientific title
The Effect of Traditional, Menstrual Cycle Phase-based, and Symptom-based Autoregulatory Resistance Training on Neuromuscular Function, Sleep and Nocturnal Physiology, and Perceived Well-being and Training Load in Healthy Female Adults
Additional trial identifiers [1] 317715 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
The menstrual cycle 342589 0
Menstrual cycle-related symptoms 342773 0
Condition category
Condition code
Metabolic and Endocrine 338733 338733 0 0
Normal metabolism and endocrine development and function
Reproductive Health and Childbirth 338734 338734 0 0
Menstruation and menopause
Musculoskeletal 338735 338735 0 0
Normal musculoskeletal and cartilage development and function

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study aims to compare the effects of traditional training prescription (TRAD), menstrual cycle phase-based training prescription (MCP), and autoregulatory prescription based upon perceived menstrual cycle symptoms (AUTO) on neuromuscular function, sleep, nocturnal physiology, and perceptions of well-being and training load.

The study was a randomised controlled trial study design. For each participant, the study duration spanned four menstrual cycles, with participant's individual timeline determined by their menstrual cycle length. This included two baseline cycles, followed by two training cycles which involved 22 resistance training sessions completed across approximately eight weeks.

The training program followed a block periodisation model, which consisted of two four-week mesocycles of increasing volume, with an unloading week during each week of testing. The initial four weeks involved higher training volumes (e.g., 10 repetitions) performed at moderate intensities (i.e., 53-68% 1RM), while the subsequent four weeks emphasised maximal strength with moderate training volumes (e.g., 5 repetitions) performed at higher intensities (i.e., 61-80% 1RM). To align the training program with each participant’s menstrual cycle, the first training session of each block was initiated by the onset of menstrual bleeding, and testing occurred during the final week of the cycle. Furthermore, sessions were scheduled according to follicular and luteal phases, with the luteal phase starting the day after ovulation. A combination of calendar-based counting and urinary ovulation testing was used to determine follicular and luteal phases.

For the TRAD and MCP groups, all repetitions, sets, and intensities were prescribed for each exercise. However, the MCP group performed higher frequencies of training during the follicular phase and lower frequencies of training during the luteal phase of the menstrual cycle (i.e., eight sessions during the follicular phase and three sessions during the luteal phase), while the TRAD and AUTO groups performed a more even distribution of training frequencies in both phases (i.e., six sessions and five sessions, respectively). For the AUTO group, participants were allowed to manipulate session intensity ±4% or 8% of 1RM (which subsequently altered total volume) based upon their perceived menstrual cycle symptoms.

All training sessions lasted approximately 60 minutes and were supervised one-on-one by a qualified exercise professional. At least one day of rest was scheduled between sessions. However, due to interindividual variations in cycle and phase length, it was not always feasible to strictly adhere to this rest period between sessions. Each session consisted of six exercises, beginning with primary exercises (i.e., exercises that underwent 3RM strength testing; e.g., trap bar deadlift, bench press), followed by secondary compound exercises (e.g., split squats, shoulder press, rows) and auxiliary exercises (e.g., lateral raise, triceps extension, biceps curls). Training intensities for the primary exercises were prescribed using loads corresponding to a percentage of estimated 1RM. For secondary compound exercises, training was prescribed using the repetitions in reserve method, whereas auxiliary exercises were prescribed using repetition maximum zones. For all exercises, participants were instructed to control the eccentric phase and to execute the concentric portion using maximal intent.

Participants were required to complete >90% of the total number of workouts to be included in the analysis.
Intervention code [1] 334548 0
Treatment: Other
Description of the comparator or control
TRAD training group
Participants allocated to the TRAD group had all training intensities and volumes prescribed. Additionally, the TRAD group completed a more even distribution of training frequency in both the follicular and luteal phase of the menstrual cycle.
Control group
Active

Outcomes
Primary outcome [1] 345944 0
Countermovement jump (CMJ): Jump height
Timepoint [1] 345944 0
CMJ performance was assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [1] 463858 0
CMJ: Flight time:Contraction time ratio
Timepoint [1] 463858 0
CMJ performance was assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [2] 463859 0
CMJ: Displacement (cm)
Timepoint [2] 463859 0
CMJ performance was assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [3] 463860 0
CMJ: Average power (W)
Timepoint [3] 463860 0
CMJ performance was assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [4] 463861 0
Heart rate (bpm)
Timepoint [4] 463861 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [5] 463862 0
Heart rate variability (rmssd)
Timepoint [5] 463862 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [6] 463863 0
Total sleep time (minutes)
Timepoint [6] 463863 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [7] 463864 0
Sleep efficiency (%)
Timepoint [7] 463864 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [8] 463865 0
Sleep onset latency (minutes)
Timepoint [8] 463865 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [9] 463866 0
Wake after sleep onset (minutes)
Timepoint [9] 463866 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [10] 463867 0
Duration of N1 sleep (minutes)
Timepoint [10] 463867 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [11] 463868 0
Duration of N2 sleep (minutes)
Timepoint [11] 463868 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [12] 463869 0
Duration of N3 sleep (minutes)
Timepoint [12] 463869 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [13] 463870 0
Duration of rapid eye movement (REM) sleep (minutes)
Timepoint [13] 463870 0
Continuous daily monitoring during nocturnal sleep throughout the intervention period.
Secondary outcome [14] 463871 0
Subjective sleep quality (1-5 Likert scale)
Timepoint [14] 463871 0
Assessed daily upon waking up the next morning (within 30 minutes) throughout the intervention period.
Secondary outcome [15] 463875 0
Session Load (arbitrary units)
Timepoint [15] 463875 0
Calculated for each of the 22 training sessions completed over the intervention period.
Secondary outcome [16] 464670 0
Monotony (arbitrary units)
Timepoint [16] 464670 0
Calculated weekly over the intervention period.
Secondary outcome [17] 464671 0
Strain (arbitrary units)
Timepoint [17] 464671 0
Calculated weekly over the intervention period.
Secondary outcome [18] 464672 0
Fatigue (1-5 Likert scale)
Timepoint [18] 464672 0
Assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [19] 464673 0
Mood (1-5 Likert scale)
Timepoint [19] 464673 0
Assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [20] 464674 0
Muscle soreness (1-5 Likert scale)
Timepoint [20] 464674 0
Assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.
Secondary outcome [21] 464675 0
Stress (1-5 Likert scale)
Timepoint [21] 464675 0
Assessed at the beginning of each of the 22 training sessions completed over the 8-week intervention period.

Eligibility
Key inclusion criteria
• Female, 18–40 years old.
• No existing health problems or circumstances that may inhibit ability to exercise or sleep. No medical condition that might increase the risk of an unusual adverse event after venous blood testing (e.g., bleeding or infection).
• Completed resistance training for at least six months, with a minimum of two training sessions per week during this period.
• Naturally cycling (i.e., not using any form of hormonal contraception) with regular menstrual cycle lengths (21–35 days) and regular menstrual flow (2–7 days per cycle). Able to demonstrate evidence of a surge in luteinising hormone.
• Not known to be pregnant and not currently planning to become pregnant during the project. If there is reason to believe pregnancy may exist, a pregnancy test may be required before participation.
• No musculoskeletal injury diagnosed by a general medical practitioner (GP) or relevant specialist within the last six months.
Minimum age
18 Years
Maximum age
40 Years
Sex
Females
Healthy volunteers
Yes
Key exclusion criteria
• Participant has a diagnosed menstrual cycle dysfunction or disorder
• Participant is pregnant
• Participant has a diagnosed injury in the previous six months that would affect exercise performance

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block randomisation
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 322255 0
University
Name [1] 322255 0
Australian Catholic University
Country [1] 322255 0
Australia
Primary sponsor type
University
Name
Australian Catholic University
Address
Country
Australia
Secondary sponsor category [1] 325168 0
None
Name [1] 325168 0
Address [1] 325168 0
Country [1] 325168 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320778 0
ACU Human Research Ethics Committee
Ethics committee address [1] 320778 0
Ethics committee country [1] 320778 0
Australia
Date submitted for ethics approval [1] 320778 0
07/04/2022
Approval date [1] 320778 0
16/09/2022
Ethics approval number [1] 320778 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151590 0
A/Prof Jonathon Weakley
Address 151590 0
Australian Catholic University, 1100 Nudgee Road, Banyo QLD 4014
Country 151590 0
Australia
Phone 151590 0
+61 414091852
Fax 151590 0
Email 151590 0
Contact person for public queries
Name 151591 0
Gabriella Munteanu
Address 151591 0
Australian Catholic University, 1100 Nudgee Road, Banyo QLD 4014
Country 151591 0
Australia
Phone 151591 0
+61434583040
Fax 151591 0
Email 151591 0
Contact person for scientific queries
Name 151592 0
Gabriella Munteanu
Address 151592 0
Australian Catholic University, 1100 Nudgee Road, Banyo QLD 4014
Country 151592 0
Australia
Phone 151592 0
+61434583040
Fax 151592 0
Email 151592 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.